Sofosbuvir más glecaprevir/pibrentasvir como terapia de rescate postrasplante hepático en pacientes con exposición previa a inhibidores de NS5A. Serie de casos

García-Juárez, Ignacio; Alonzo-García, Carlos; Contreras, Alan G.; Romero-Hernández, Fernanda; Servín-Rojas, Maximiliano; Fernández-Ramírez, Alfonso; Ruiz, Isaac.
Gac. méd. Méx ; 159(4): 338-344, jul.-ago. 2023. tab, graf
Artículo en Español | LILACS-Express | ID: biblio-1514134

Documentos relacionados

  1. Sofosbuvir plus glecaprevir/pibrentasvir as salvage therapy after liver transplantation in NS5A inhibitor-experienced patients. A case series.
  2. Concomitant use of direct-acting antivirals (DAA) and central nervous system drugs in patients with hepatitis C virus infection.
  3. Pangenotypic direct-acting antiviral agents for mixed genotype hepatitis C infection: A real-world effectiveness analysis.
  4. Non-pharmacologic direct cost of a simplified strategy with glecaprevir/pibrentasvir for 8 weeks in naïve non-cirrhotic patients with hepatitis C implemented in clinical practice. The Just SIMPLE Study
  5. [Two case reports of chronic hepatitis C retreatment].